Cambridge Investment Research Advisors
SRDX

Cambridge Investment Research Advisors’s Surmodics SRDX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,780
Closed -$217K – 3199
2022
Q1 		$217K Hold
4,780
– – ﹤0.01% 2803
2021
Q4 		$230K Hold
4,780
– – ﹤0.01% 2757
2021
Q3 		$266K Buy
+4,780
New +$266K ﹤0.01% 2558

Other funds holding SRDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Cambridge Investment Research Advisors's SRDX Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Surmodics (SRDX) in Q2 2022, closing a stake of 4,780 shares — an estimated $217K sold.

Cambridge Investment Research Advisors first reported a position in SRDX in Q3 2021 and held it in 3 quarters. The position peaked at $266K in Q3 2021. 129 funds tracked by Wall St. Rank hold SRDX as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining Surmodics position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 4,780 Surmodics shares in Q2 2022, an estimated $217K.
  • Cambridge Investment Research Advisors first reported a position in Surmodics in Q3 2021 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Surmodics position peaked at $266K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Surmodics as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.